BC Neuroimmunology

BCNI Patient ID: «BCNI_Patient_ID»	Patient Full Name: «Patient_Full_Name»			Report Status: *FINAL*
Health Care Number: «Health_Care_Number»	Date of Birth: «DOB»	Sex: «Sex»		Patient Type: *Not Provided*
Ordering Physician(s) and Contact Information: «Ordering_Physician»				Sample Collection Date: *«Sample_Collection_Date»*
Referring Hospital/Laboratory: «Referring_HospitalLab»		City/Province Code: «CityProvince_Code»		Sample Received Date: *«Sample_Received_Date»*

PATIENT TEST REPORT

SAMPLE NO.	TEST NAME	RESULT (VALUE)	UNIT	REFERENCE VALUE	ACCESSION NO.
«Sample_No»	NfL (Neurofilament light chain)	**«Result»** «Result_Quant_ngL» ng/L	ng/L	See below	«Accession_No»
Assay Date: «Assay_Date»	**Result Date:** «Result_Date»			**Sample Type:** Plasma	

Results Interpretation:

NfL Quantitative: Age group
20 – 29 (≤ 8.4 ng/L)
30 – 39 (≤ 11.4 ng/L)
40 – 49 (≤ 15.4 ng/L)
50 – 59 (≤ 20.8 ng/L)
60 – 69 (≤ 28.0 ng/L)
70 – 79 (≤ 37.9 ng/L)
≥ 80 (≤ 51.2 ng/L)

Interpretive Comments:

Elevated NfL is not a disease specific factor and may be caused by a neurodegenerative disease or traumatic brain injury, or after surgery. Results should be interpreted in conjunction with clinical signs and symptoms.

NfL levels measured in the evening may be more than 10% lower than those measured in the morning (Benedict et al 2020).

Higher levels of NfL can occur in patients with a history of stroke, atrial fibrillation, myocardial infarction, chronic kidney disease, pregnancy, and diabetes. Lower levels may be observed in persons with BMI ≥ 30 (Syrjanen et al 2022).

Laboratory Notes:

Lumipulse® G bead-based assay kits specific for each biomarker were used to detect the levels of the biomarker in the patient sample. Bead-based immunoassay testing was performed on the Lumipulse®G1200 instrument.

This sample was sent to a referral laboratory (Neurocode USA – CLIA#: 50D2158817) for testing.

This test was developed, and its performance characteristics determined by Neurocode USA, Inc. at Northwest Laboratory dba Avero Diagnostics. It has not been cleared or approved by the FDA.

Address	Laboratory Director	DAP ID	CAP ID	CLIA ID
S-157, 2211 Wesbrook Mall Vancouver BC V6T 2B5	Hans Frykman, MD, PhD, FRCPC	0612LM	8114351	99D2279923

BCNI Patient ID: «BCNI_Patient_ID»	Patient Full Name: «Patient_Full_Name»		Report Status: *FINAL*
Health Care Number: «Health_Care_Number»	Date of Birth: «DOB»	Sex: «Sex»	Patient Type: *Not Provided*
Ordering Physician(s) and Contact Information: «Ordering_Physician»			Sample Collection Date: *«Sample_Collection_Date»*
Referring Hospital/Laboratory: «Referring_HospitalLab»	City/Province Code: «CityProvince_Code»		Sample Received Date: *«Sample_Received_Date»*

References:

Benedict C, Blennow K, Zetterberg H, Cedernaes J. Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men. Neurology. 2020;94(11). doi:10.1212/wnl.0000000000008866.

Bornhorst JA, Figdore D, Campbell MR, Pazdernik VK, Mielke MM, Petersen RC, Algeciras-Schimnich A. Plasma neurofilament light chain (NfL) reference interval determination in an Age stratified cognitively unimpaired cohort. Clin Chim Acta. 2022 Oct 1;535:153-156. doi: 10.1016/j.cca.2022.08.017.

Syrjanen JA, Campbell MR, Algeciras-Schimnich A, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 2022;18(6):1128-1140. doi:10.1002/alz.12466.

"Fujirebio Expands Its Assay Menu in the Field of Neurodegenerative Diseases with the Launch of the Fully Automated Lumipulse® G NFL CSF and Lumipulse® g NFL Blood Tests." Business Wire, 28 Mar 2023, www.businesswire.com/news/home/20230327005717/en.

END OF REPORT

Address	Laboratory Director	DAP ID	CAP ID	CLIA ID
S-157, 2211 Wesbrook Mall Vancouver BC V6T 2B5	Hans Frykman, MD, PhD, FRCPC	0612LM	8114351	99D2279923